British BioTech company and King’s College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers
Nuclide Therapeutics has raised €5.7M across 1 funding round from 1 investor, most recently a round in Sep 2025. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-09-23 | Other |
| €5.7M |
| Marathon Beteiligungs AG |
| View deal → |
